This is the latest episode of the free DDW narrated podcast, titled “The far-reaching impact of drug discovery technology”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “Accelerating time to market through digitalisation”, “… Read More
A world-first ‘epigenetic map’ of the human genome could lead to breakthroughs in new diagnoses and treatments, say UK scientists. This new resource for medical researchers will be created though a new strategic partnership between the UK government, Oxford Nanopore Technologies, UK Biobank, NHS England and Genomics… Read More
The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s most exciting news stories all represent innovative solutions to the… Read More
News round-up for 18-22 November by DDW Senior Digital Content Editor Diana Spencer. This week’s most exciting news stories all represent innovative solutions to the treatment of disease, proving that ‘thinking outside the box’ can by the key to success in drug discovery. The top stories:… Read More
Researchers have identified 330 potential cancer-driving genes, 74 of which are newly associated with cancer. The findings highlight the potential to develop new, more targeted treatment options and provide hope that existing cancer treatments, such as PARP inhibitors, could be extended to thousands more patients. Read More
Jason Park, Ph.D, CEO & Co-Founder of Empress Therapeutics and Operating Partner, Flagship Pioneering, examines why technologies such as artificial intelligence (AI) and machine learning (ML) will prove essential for the discovery of new small molecule medicines. For the better part of the last century, drug discovery was focused… Read More
Kathryn L Chapman, Head of Discovery Biology & Jürgen Moll CSO at Tesselate Bio, explore alternative approaches to synthetic lethality to target cancer cells that use alternative lengthening of telomersin. Synthetic lethality and targeted drugs are a clinically established approach Synthetic lethality (SL) is an established, clinical and commercial approach… Read More
Researchers have discovered that an eczema-linked protein helps ovarian cancer manipulate its environment to resist immunotherapy, suggesting the potential for a skin drug-based treatment. Scientists at the Icahn School of Medicine at Mount Sinai used spatial genomics technology and preclinical animal models, with tumour specimens from… Read More
New research has detailed each type of cancer mutation that causes drug resistance, helping to uncover targets for drug development and identify potential effective second-line therapies. In a new large-scale study, researchers from the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), Open Targets, and collaborators… Read More
DDW Editor Reece Armstrong speaks to Dr Caroline Kӧhrer, Vice President, Discovery Platform, Alltrna, about the biology behind tRNAs and how they could help produce a medicine that could treat thousands of rare diseases that share the same genetic mutation. RA: Why are tRNA molecules so important for rare genetic… Read More
A team of researchers from the University of Nottingham have received funding to explore the capabilities of quantum computing for developing new drugs for myotonic dystrophy. Building on an initial award of over £1 ($1.3) million, a team of researchers from the University of Nottingham, with… Read More
The Nobel Assembly at Karolinska Institutet has awarded the 2024 Nobel Prize in Physiology or Medicine jointly to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation. Victor Ambros is Silverman Professor of Natural Science at the University… Read More
DDW Editor Reece Armstrong speaks to Dr Sandro Ataide, Senior Lecturer in Structural Biology at the School of Life and Environmental Sciences Sydney Drug Discovery Initiative (DDI). Earlier this year, Dr Ataide’s team developed a gene-editing tool called SeekRNA that uses a programmable ribonucleic acid (RNA) strand that can directly… Read More
Scientists have pinpointed thousands of genetic changes in a gene that may increase a person’s risk of developing breast and ovarian cancer and also identified new potential therapeutic targets. Researchers from the Wellcome Sanger Institute and their collaborators focused on the ‘cancer protection’ gene RAD51C, known… Read More
A gene therapy developed by University of Florida scientists restored useful vision to most patients with rare condition Leber congenital amaurosis type I (LCA1) in a small trial. Patients who received the highest dose of the gene therapy saw up to a 10,000-fold improvement in their… Read More
Vesper Bio has completed a Phase I study for its lead candidate, VES001, a potentially disease-modifying treatment for frontotemporal dementia patients with mutations in the progranulin gene (FTD(GRN)). Frontotemporal dementia is the most common cause of dementia in people under the age of 60. FTD(GRN), which… Read More
